Severe, Atypical Skin Reactions With Amivantamab in NSCLC Severe, Atypical Skin Reactions With Amivantamab in NSCLC

Some of the cutaneous adverse events to amivantamab, which targets both EGFR and MET, can be severe and have atypical presentations, which led to dose reductions in five of six cases.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news